Skip to main content
Top
Published in: Inflammation 3/2012

01-06-2012

Effects of Lower Concentration Thrombin on High-Mobility Group Box 1 Protein-Mediated Inflammatory Responses

Author: Jong-Sup Bae

Published in: Inflammation | Issue 3/2012

Login to get access

Abstract

As a late mediator of inflammation, the high-mobility group box 1 protein (HMGB1) plays a key role in the inflammatory responses to tissue injury and infection by inducing and extending the production of proinflammatory cytokines. It has been observed that lower concentration thrombin mediates anti-inflammatory activities. The aim of this study was to investigate whether lower concentration thrombin could modulate HMGB1 expression and could inhibit HMGB1-mediated inflammatory responses in human umbilical vein endothelial cells (HUVECs). Here, results showed that lower concentration thrombin or thrombin receptor agonist peptide inhibits lipopolysaccharide-induced HMGB1 release from HUVECs. And lower concentration thrombin has inhibitory effects not only on the expression of cell adhesion molecules but also on neutrophils adhesion and migration toward HUVECs in response to HMGB1. Interestingly, the HMGB1-induced nuclear factor kappa B activation and tumor necrosis factor-alpha release from HUVECs were inhibited by lower concentration thrombin. Given these results, lower concentration thrombin could be a strong candidate as a therapeutic agent for various systemic inflammatory diseases.
Literature
1.
go back to reference Wang, H., O. Bloom, M. Zhang, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248–251.PubMedCrossRef Wang, H., O. Bloom, M. Zhang, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248–251.PubMedCrossRef
2.
go back to reference Muller, S., P. Scaffidi, B. Degryse, et al. 2001. New EMBO members’ review: The double life of HMGB1 chromatin protein: Architectural factor and extracellular signal. EMBO Journal 20: 4337–4340.PubMedCrossRef Muller, S., P. Scaffidi, B. Degryse, et al. 2001. New EMBO members’ review: The double life of HMGB1 chromatin protein: Architectural factor and extracellular signal. EMBO Journal 20: 4337–4340.PubMedCrossRef
3.
go back to reference Harris, H.E., and A. Raucci. 2006. Alarmin(g) news about danger: Workshop on innate danger signals and HMGB1. EMBO Reports 7: 774–778.PubMed Harris, H.E., and A. Raucci. 2006. Alarmin(g) news about danger: Workshop on innate danger signals and HMGB1. EMBO Reports 7: 774–778.PubMed
4.
go back to reference DeMarco, R.A., M.P. Fink, and M.T. Lotze. 2005. Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Molecular Immunology 42: 433–444.PubMedCrossRef DeMarco, R.A., M.P. Fink, and M.T. Lotze. 2005. Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Molecular Immunology 42: 433–444.PubMedCrossRef
5.
go back to reference Scaffidi, P., T. Misteli, and M.E. Bianchi. 2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191–195.PubMedCrossRef Scaffidi, P., T. Misteli, and M.E. Bianchi. 2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191–195.PubMedCrossRef
6.
go back to reference Andersson, U., H. Wang, K. Palmblad, et al. 2000. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. The Journal of Experimental Medicine 192: 565–570.PubMedCrossRef Andersson, U., H. Wang, K. Palmblad, et al. 2000. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. The Journal of Experimental Medicine 192: 565–570.PubMedCrossRef
7.
go back to reference Fiuza, C., M. Bustin, S. Talwar, et al. 2003. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101: 2652–2660.PubMedCrossRef Fiuza, C., M. Bustin, S. Talwar, et al. 2003. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101: 2652–2660.PubMedCrossRef
8.
go back to reference Park, J.S., D. Svetkauskaite, Q. He, et al. 2004. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. Journal of Biological Chemistry 279: 7370–7377.PubMedCrossRef Park, J.S., D. Svetkauskaite, Q. He, et al. 2004. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. Journal of Biological Chemistry 279: 7370–7377.PubMedCrossRef
9.
go back to reference Vallet, B. 2003. Bench-to-bedside review: Endothelial cell dysfunction in severe sepsis: A role in organ dysfunction? Critical Care 7: 130–138.PubMedCrossRef Vallet, B. 2003. Bench-to-bedside review: Endothelial cell dysfunction in severe sepsis: A role in organ dysfunction? Critical Care 7: 130–138.PubMedCrossRef
10.
go back to reference Ross, R. 1993. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 801–809.PubMedCrossRef Ross, R. 1993. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 801–809.PubMedCrossRef
11.
go back to reference Wu, K.K., and P. Thiagarajan. 1996. Role of endothelium in thrombosis and hemostasis. Annual Review of Medicine 47: 315–331.PubMedCrossRef Wu, K.K., and P. Thiagarajan. 1996. Role of endothelium in thrombosis and hemostasis. Annual Review of Medicine 47: 315–331.PubMedCrossRef
12.
go back to reference Yamagami, H., S. Yamagami, T. Inoki, S. Amano, and K. Miyata. 2003. The effects of proinflammatory cytokines on cytokine-chemokine gene expression profiles in the human corneal endothelium. Investigative Ophthalmology & Visual Science 44: 514–520.CrossRef Yamagami, H., S. Yamagami, T. Inoki, S. Amano, and K. Miyata. 2003. The effects of proinflammatory cytokines on cytokine-chemokine gene expression profiles in the human corneal endothelium. Investigative Ophthalmology & Visual Science 44: 514–520.CrossRef
13.
go back to reference Zeuke, S., A.J. Ulmer, S. Kusumoto, H.A. Katus, and H. Heine. 2002. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovascular Research 56: 126–134.PubMedCrossRef Zeuke, S., A.J. Ulmer, S. Kusumoto, H.A. Katus, and H. Heine. 2002. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovascular Research 56: 126–134.PubMedCrossRef
14.
go back to reference Chen, C.C., and A.M. Manning. 1995. Transcriptional regulation of endothelial cell adhesion molecules: A dominant role for NF-kappa B. Agents and Actions. Supplements 47: 135–141.PubMed Chen, C.C., and A.M. Manning. 1995. Transcriptional regulation of endothelial cell adhesion molecules: A dominant role for NF-kappa B. Agents and Actions. Supplements 47: 135–141.PubMed
15.
16.
go back to reference Macfarlane, S.R., M.J. Seatter, T. Kanke, G.D. Hunter, and R. Plevin. 2001. Proteinase-activated receptors. Pharmacological Reviews 53: 245–282.PubMed Macfarlane, S.R., M.J. Seatter, T. Kanke, G.D. Hunter, and R. Plevin. 2001. Proteinase-activated receptors. Pharmacological Reviews 53: 245–282.PubMed
17.
go back to reference Ossovskaya, V.S., and N.W. Bunnett. 2004. Protease-activated receptors: Contribution to physiology and disease. Physiological Reviews 84: 579–621.PubMedCrossRef Ossovskaya, V.S., and N.W. Bunnett. 2004. Protease-activated receptors: Contribution to physiology and disease. Physiological Reviews 84: 579–621.PubMedCrossRef
18.
go back to reference Steinhoff, M., J. Buddenkotte, V. Shpacovitch, et al. 2005. Proteinase-activated receptors: Transducers of proteinase-mediated signaling in inflammation and immune response. Endocrine Reviews 26: 1–43.PubMedCrossRef Steinhoff, M., J. Buddenkotte, V. Shpacovitch, et al. 2005. Proteinase-activated receptors: Transducers of proteinase-mediated signaling in inflammation and immune response. Endocrine Reviews 26: 1–43.PubMedCrossRef
19.
go back to reference Coughlin, S.R. 2005. Protease-activated receptors in hemostasis, thrombosis and vascular biology. Journal of Thrombosis and Haemostasis 3: 1800–1814.PubMedCrossRef Coughlin, S.R. 2005. Protease-activated receptors in hemostasis, thrombosis and vascular biology. Journal of Thrombosis and Haemostasis 3: 1800–1814.PubMedCrossRef
20.
go back to reference Bae, J.S., Y.U. Kim, M.K. Park, and A.R. Rezaie. 2009. Concentration dependent dual effect of thrombin in endothelial cells via Par-1 and Pi3 kinase. Journal of Cellular Physiology 219: 744–751.PubMedCrossRef Bae, J.S., Y.U. Kim, M.K. Park, and A.R. Rezaie. 2009. Concentration dependent dual effect of thrombin in endothelial cells via Par-1 and Pi3 kinase. Journal of Cellular Physiology 219: 744–751.PubMedCrossRef
21.
go back to reference Bae, J.S., L. Yang, C. Manithody, and A.R. Rezaie. 2007. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 110: 3909–3916.PubMedCrossRef Bae, J.S., L. Yang, C. Manithody, and A.R. Rezaie. 2007. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 110: 3909–3916.PubMedCrossRef
22.
go back to reference Feistritzer, C., and M. Riewald. 2005. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 105: 3178–3184.PubMedCrossRef Feistritzer, C., and M. Riewald. 2005. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 105: 3178–3184.PubMedCrossRef
23.
go back to reference Bae, J.S. 2011. Inhibitory effect of thrombin on the expression of secretory group IIA phospholipase A. Journal of Cellular Biochemistry 112: 2502–2507.PubMedCrossRef Bae, J.S. 2011. Inhibitory effect of thrombin on the expression of secretory group IIA phospholipase A. Journal of Cellular Biochemistry 112: 2502–2507.PubMedCrossRef
24.
go back to reference Bae, J.S., and A.R. Rezaie. 2011. Activated protein C inhibits high mobility group box 1 signaling in endothelial cells. Blood 118: 3952–3959.PubMedCrossRef Bae, J.S., and A.R. Rezaie. 2011. Activated protein C inhibits high mobility group box 1 signaling in endothelial cells. Blood 118: 3952–3959.PubMedCrossRef
25.
go back to reference Akeson, A.L., and C.W. Woods. 1993. A fluorometric assay for the quantitation of cell adherence to endothelial cells. Journal of Immunological Methods 163: 181–185.PubMedCrossRef Akeson, A.L., and C.W. Woods. 1993. A fluorometric assay for the quantitation of cell adherence to endothelial cells. Journal of Immunological Methods 163: 181–185.PubMedCrossRef
26.
go back to reference Che, W., N. Lerner-Marmarosh, Q. Huang, et al. 2002. Insulin-like growth factor-1 enhances inflammatory responses in endothelial cells: Role of Gab1 and MEKK3 in TNF-alpha-induced c-Jun and NF-kappaB activation and adhesion molecule expression. Circulation Research 90: 1222–1230.PubMedCrossRef Che, W., N. Lerner-Marmarosh, Q. Huang, et al. 2002. Insulin-like growth factor-1 enhances inflammatory responses in endothelial cells: Role of Gab1 and MEKK3 in TNF-alpha-induced c-Jun and NF-kappaB activation and adhesion molecule expression. Circulation Research 90: 1222–1230.PubMedCrossRef
27.
go back to reference Mullins, G.E., J. Sunden-Cullberg, A.S. Johansson, et al. 2004. Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scandinavian Journal of Immunology 60: 566–573.PubMedCrossRef Mullins, G.E., J. Sunden-Cullberg, A.S. Johansson, et al. 2004. Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scandinavian Journal of Immunology 60: 566–573.PubMedCrossRef
28.
go back to reference Yang, J., C. Huang, H. Jiang, and J. Ding. 2010. Statins attenuate high mobility group box-1 protein induced vascular endothelial activation: A key role for TLR4/NF-kappaB signaling pathway. Molecular and Cellular Biochemistry 345: 189–195.PubMedCrossRef Yang, J., C. Huang, H. Jiang, and J. Ding. 2010. Statins attenuate high mobility group box-1 protein induced vascular endothelial activation: A key role for TLR4/NF-kappaB signaling pathway. Molecular and Cellular Biochemistry 345: 189–195.PubMedCrossRef
29.
go back to reference Treutiger, C.J., G.E. Mullins, A.S. Johansson, et al. 2003. High mobility group 1 B-box mediates activation of human endothelium. Journal of Internal Medicine 254: 375–385.PubMedCrossRef Treutiger, C.J., G.E. Mullins, A.S. Johansson, et al. 2003. High mobility group 1 B-box mediates activation of human endothelium. Journal of Internal Medicine 254: 375–385.PubMedCrossRef
30.
go back to reference Javaid, K., A. Rahman, K.N. Anwar, R.S. Frey, R.D. Minshall, and A.B. Malik. 2003. Tumor necrosis factor-alpha induces early-onset endothelial adhesivity by protein kinase Czeta-dependent activation of intercellular adhesion molecule-1. Circulation Research 92: 1089–1097.PubMedCrossRef Javaid, K., A. Rahman, K.N. Anwar, R.S. Frey, R.D. Minshall, and A.B. Malik. 2003. Tumor necrosis factor-alpha induces early-onset endothelial adhesivity by protein kinase Czeta-dependent activation of intercellular adhesion molecule-1. Circulation Research 92: 1089–1097.PubMedCrossRef
31.
go back to reference Lockyer, J.M., J.S. Colladay, W.L. Alperin-Lea, T. Hammond, and A.J. Buda. 1998. Inhibition of nuclear factor-kappaB-mediated adhesion molecule expression in human endothelial cells. Circulation Research 82: 314–320.PubMed Lockyer, J.M., J.S. Colladay, W.L. Alperin-Lea, T. Hammond, and A.J. Buda. 1998. Inhibition of nuclear factor-kappaB-mediated adhesion molecule expression in human endothelial cells. Circulation Research 82: 314–320.PubMed
32.
go back to reference Park, J.S., F. Gamboni-Robertson, Q. He, et al. 2006. High mobility group box 1 protein interacts with multiple Toll-like receptors. American Journal of Physiology. Cell Physiology 290: C917–C924.PubMedCrossRef Park, J.S., F. Gamboni-Robertson, Q. He, et al. 2006. High mobility group box 1 protein interacts with multiple Toll-like receptors. American Journal of Physiology. Cell Physiology 290: C917–C924.PubMedCrossRef
33.
go back to reference Ossovskaya, V.S., N.W. Bunnett, L. de Garavilla, et al. 2004. Protease-activated receptors: Contribution to physiology and disease. Physiological Reviews 84: 579–621.PubMedCrossRef Ossovskaya, V.S., N.W. Bunnett, L. de Garavilla, et al. 2004. Protease-activated receptors: Contribution to physiology and disease. Physiological Reviews 84: 579–621.PubMedCrossRef
34.
go back to reference Shankar, R., C.A. de la Motte, E.J. Poptic, and P.E. DiCorleto. 1994. Thrombin receptor-activating peptides differentially stimulate platelet-derived growth factor production, monocytic cell adhesion, and E-selectin expression in human umbilical vein endothelial cells. Journal of Biological Chemistry 269: 13936–13941.PubMed Shankar, R., C.A. de la Motte, E.J. Poptic, and P.E. DiCorleto. 1994. Thrombin receptor-activating peptides differentially stimulate platelet-derived growth factor production, monocytic cell adhesion, and E-selectin expression in human umbilical vein endothelial cells. Journal of Biological Chemistry 269: 13936–13941.PubMed
35.
go back to reference Bae, J.S., and A.R. Rezaie. 2008. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thrombosis and Haemostasis 100: 101–109.PubMed Bae, J.S., and A.R. Rezaie. 2008. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thrombosis and Haemostasis 100: 101–109.PubMed
36.
go back to reference Vu, T.K., D.T. Hung, V.I. Wheaton, and S.R. Coughlin. 1991. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64: 1057–1068.PubMedCrossRef Vu, T.K., D.T. Hung, V.I. Wheaton, and S.R. Coughlin. 1991. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64: 1057–1068.PubMedCrossRef
37.
go back to reference Zain, J., Y.Q. Huang, X. Feng, M.L. Nierodzik, J.J. Li, and S. Karpatkin. 2000. Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. Blood 95: 3133–3138.PubMed Zain, J., Y.Q. Huang, X. Feng, M.L. Nierodzik, J.J. Li, and S. Karpatkin. 2000. Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. Blood 95: 3133–3138.PubMed
38.
go back to reference Striggow, F., M. Riek, J. Breder, P. Henrich-Noack, K.G. Reymann, and G. Reiser. 2000. The protease thrombin is an endogenous mediator of hippocampal neuroprotection against ischemia at low concentrations but causes degeneration at high concentrations. Proceedings of the National Academy of Sciences of the United States of America 97: 2264–2269.PubMedCrossRef Striggow, F., M. Riek, J. Breder, P. Henrich-Noack, K.G. Reymann, and G. Reiser. 2000. The protease thrombin is an endogenous mediator of hippocampal neuroprotection against ischemia at low concentrations but causes degeneration at high concentrations. Proceedings of the National Academy of Sciences of the United States of America 97: 2264–2269.PubMedCrossRef
39.
go back to reference Ding, H.S., and J. Yang. 2010. High mobility group box-1 and cardiovascular diseases. Saudi Medical Journal 31: 486–489.PubMed Ding, H.S., and J. Yang. 2010. High mobility group box-1 and cardiovascular diseases. Saudi Medical Journal 31: 486–489.PubMed
40.
go back to reference El Gazzar, M. 2007. HMGB1 modulates inflammatory responses in LPS-activated macrophages. Inflammation Research 56: 162–167.PubMedCrossRef El Gazzar, M. 2007. HMGB1 modulates inflammatory responses in LPS-activated macrophages. Inflammation Research 56: 162–167.PubMedCrossRef
41.
go back to reference Rouhiainen, A., J. Kuja-Panula, E. Wilkman, et al. 2004. Regulation of monocyte migration by amphoterin (HMGB1). Blood 104: 1174–1182.PubMedCrossRef Rouhiainen, A., J. Kuja-Panula, E. Wilkman, et al. 2004. Regulation of monocyte migration by amphoterin (HMGB1). Blood 104: 1174–1182.PubMedCrossRef
42.
go back to reference Degryse, B., and M. de Virgilio. 2003. The nuclear protein HMGB1, a new kind of chemokine? FEBS Letters 553: 11–17.PubMedCrossRef Degryse, B., and M. de Virgilio. 2003. The nuclear protein HMGB1, a new kind of chemokine? FEBS Letters 553: 11–17.PubMedCrossRef
43.
go back to reference Yang, H., M. Ochani, J. Li, et al. 2004. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proceedings of the National Academy of Sciences of the United States of America 101: 296–301.PubMedCrossRef Yang, H., M. Ochani, J. Li, et al. 2004. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proceedings of the National Academy of Sciences of the United States of America 101: 296–301.PubMedCrossRef
44.
go back to reference Hortelano, S., R. Lopez-Fontal, P.G. Traves, et al. 2010. ILK mediates LPS-induced vascular adhesion receptor expression and subsequent leucocyte trans-endothelial migration. Cardiovascular Research 86: 283–292.PubMedCrossRef Hortelano, S., R. Lopez-Fontal, P.G. Traves, et al. 2010. ILK mediates LPS-induced vascular adhesion receptor expression and subsequent leucocyte trans-endothelial migration. Cardiovascular Research 86: 283–292.PubMedCrossRef
45.
go back to reference Dal-Secco, D., A. Freitas, M.A. Abreu, et al. 2010. Reduction of ICAM-1 expression by carbon monoxide via soluble guanylate cyclase activation accounts for modulation of neutrophil migration. Naunyn-Schmiedeberg’s Archives of Pharmacology 381: 483–493.PubMedCrossRef Dal-Secco, D., A. Freitas, M.A. Abreu, et al. 2010. Reduction of ICAM-1 expression by carbon monoxide via soluble guanylate cyclase activation accounts for modulation of neutrophil migration. Naunyn-Schmiedeberg’s Archives of Pharmacology 381: 483–493.PubMedCrossRef
46.
go back to reference Park, J.S., J. Arcaroli, H.K. Yum, et al. 2003. Activation of gene expression in human neutrophils by high mobility group box 1 protein. American Journal of Physiology. Cell Physiology 284: C870–C879.PubMed Park, J.S., J. Arcaroli, H.K. Yum, et al. 2003. Activation of gene expression in human neutrophils by high mobility group box 1 protein. American Journal of Physiology. Cell Physiology 284: C870–C879.PubMed
47.
go back to reference Langer, H.F., and T. Chavakis. 2009. Leukocyte–endothelial interactions in inflammation. Journal of Cellular and Molecular Medicine 13: 1211–1220.PubMedCrossRef Langer, H.F., and T. Chavakis. 2009. Leukocyte–endothelial interactions in inflammation. Journal of Cellular and Molecular Medicine 13: 1211–1220.PubMedCrossRef
48.
go back to reference Pardi, R., L. Inverardi, and J.R. Bender. 1992. Regulatory mechanisms in leukocyte adhesion: Flexible receptors for sophisticated travelers. Immunology Today 13: 224–230.PubMedCrossRef Pardi, R., L. Inverardi, and J.R. Bender. 1992. Regulatory mechanisms in leukocyte adhesion: Flexible receptors for sophisticated travelers. Immunology Today 13: 224–230.PubMedCrossRef
Metadata
Title
Effects of Lower Concentration Thrombin on High-Mobility Group Box 1 Protein-Mediated Inflammatory Responses
Author
Jong-Sup Bae
Publication date
01-06-2012
Publisher
Springer US
Published in
Inflammation / Issue 3/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-011-9414-5

Other articles of this Issue 3/2012

Inflammation 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.